Rachel brings more than 20 years of diverse leadership and management experience from a variety of sectors, including global public health and biotech. She leads portfolio strategy, partnerships, and global product development efforts at Seagen, leveraging her experience to advance and deliver on corporate, portfolio, and product strategies. In this capacity, Rachel also supported Seagen’s transition to a global, multi-product oncology company.
Previously, Rachel held senior strategic and operational roles at the Bill & Melinda Gates Foundation, where she oversaw strategy and business operations for the Malaria and Neglected Infectious Diseases programs and led alliances with product development organizations and country Ministries of Health. She also drove the successful global development and commercialization strategy for Prolia® (denosumab) at Amgen. Earlier in her career, she was a management consultant with Accenture and Deloitte Consulting, working with clients such as Microsoft, Hewlett-Packard, Immunex, Sprint, and Starbucks.
Rachel holds an M.B.A. from Pepperdine University and B.A. in Business from the University of Washington.